Marcello Tiseo1, Angela Damato2, Lucia Longo3, Fausto Barbieri4, Federica Bertolini4, Alessandro Stefani5, Mario Migaldi6, Letizia Gnetti7, Roberta Camisa2, Paola Bordi2, Sebastiano Buti2, Giulio Rossi8. 1. Medical Oncology Unit, Azienda Ospedaliero-Universitaria, Parma, Italy. Electronic address: mtiseo@ao.pr.it. 2. Medical Oncology Unit, Azienda Ospedaliero-Universitaria, Parma, Italy. 3. Medical Oncology Unit, Azienda USL Modena, Hospital "Ramazzini", Carpi, Italy. 4. Department of Oncology, Haematology and Respiratory Diseases Clinic, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy. 5. Operative Unit of Thoracic Surgery, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy. 6. Operative Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy. 7. Section of Anatomy and Pathology, Azienda Ospedaliero-Universitaria, Parma, Italy. 8. Unit of Pathologic Anatomy, Azienda USL Valle d'Aosta, Regional Hospital "Parini", Aosta, Italy.
Abstract
INTRODUCTION: Thymic epithelial tumors (TETs) are rare neoplasms with different prognosis lacking consistent molecular alterations possibly leading to targeted therapy. We collected a consecutive series of TETs aimed at investigating the mutational status of druggable genes (EGFR, c-KIT, KRAS, BRAF, PDGFR-alpha and -beta, HER2 and c-MET) and the expression of ALK and PD-L1. PATIENTS AND METHODS: One hundred twelve consecutive cases of TETs and relative clinico-pathologic features were collected. Immunohistochemical expression of ALK (clone D5F3) and PD-L1 (clone E1L3N), molecular analysis of EGFR (exons 18-21), c-KIT (exons 9,11,13,14,17), KRAS (exon 2), BRAF (exon 15), PDGFR-alpha (exon 12) and -beta (exons 12, 14, 18), HER-2 (exons 19 and 20) and c-MET (exons 14, 17, 18, 19) mutations were performed. Immuno-molecular results were then statistically matched with clinico-pathologic characteristics. RESULTS: Patients were male in 54% of cases, with a median age of 61 years (range 19-83) and affected mainly by thymoma (78%) in stage II (45%). At molecular analysis, there were 4 c-KIT mutations (occurring in exon 11 V559A, L576P, Y553N and exon 17 D820E) in thymic carcinomas (typeC), but not in other tumor types (p=0.003). No mutations were detected in other genes and none case was ALK positive. Twenty-nine (26%) cases were PD-L1 positive (65% of thymic carcinomas and 18% of thymomas). High PD-L1 expression was statistically associated with WHO classification stage type C (p<0.001) and Masaoka stage III-IV disease (p=0.007). In univariate analysis, WHO classification type C, advanced Masaoka stage and absence of myasthenia, but not PD-L1 expressions were correlated with worse survival; at multivariate analysis, only WHO type C confirmed its negative prognostic role. CONCLUSION: A subset of TETs as thymic carcinomas can harbor c-KIT mutations and elevated PD-L1 expression that could represent targets of potential therapeutic use. Copyright Â
INTRODUCTION:Thymic epithelial tumors (TETs) are rare neoplasms with different prognosis lacking consistent molecular alterations possibly leading to targeted therapy. We collected a consecutive series of TETs aimed at investigating the mutational status of druggable genes (EGFR, c-KIT, KRAS, BRAF, PDGFR-alpha and -beta, HER2 and c-MET) and the expression of ALK and PD-L1. PATIENTS AND METHODS: One hundred twelve consecutive cases of TETs and relative clinico-pathologic features were collected. Immunohistochemical expression of ALK (clone D5F3) and PD-L1 (clone E1L3N), molecular analysis of EGFR (exons 18-21), c-KIT (exons 9,11,13,14,17), KRAS (exon 2), BRAF (exon 15), PDGFR-alpha (exon 12) and -beta (exons 12, 14, 18), HER-2 (exons 19 and 20) and c-MET (exons 14, 17, 18, 19) mutations were performed. Immuno-molecular results were then statistically matched with clinico-pathologic characteristics. RESULTS:Patients were male in 54% of cases, with a median age of 61 years (range 19-83) and affected mainly by thymoma (78%) in stage II (45%). At molecular analysis, there were 4 c-KIT mutations (occurring in exon 11 V559A, L576P, Y553N and exon 17 D820E) in thymic carcinomas (typeC), but not in other tumor types (p=0.003). No mutations were detected in other genes and none case was ALK positive. Twenty-nine (26%) cases were PD-L1 positive (65% of thymic carcinomas and 18% of thymomas). High PD-L1 expression was statistically associated with WHO classification stage type C (p<0.001) and Masaoka stage III-IV disease (p=0.007). In univariate analysis, WHO classification type C, advanced Masaoka stage and absence of myasthenia, but not PD-L1 expressions were correlated with worse survival; at multivariate analysis, only WHO type C confirmed its negative prognostic role. CONCLUSION: A subset of TETs as thymic carcinomas can harbor c-KIT mutations and elevated PD-L1 expression that could represent targets of potential therapeutic use. Copyright Â
Authors: Dwight Owen; Benjamin Chu; Amy M Lehman; Lakshmanan Annamalai; Jennifer H Yearley; Konstantin Shilo; Gregory A Otterson Journal: J Thorac Oncol Date: 2018-04-24 Impact factor: 15.609
Authors: Giovanni Bocchialini; Ana-Iris Schiefer; Leonhard Müllauer; Jürgen Thanner; Jonas Bauer; Felizia Thaler; Maria Laggner; Cecilia Veraar; Walter Klepetko; Konrad Hötzenecker; José Ramon Matilla; Hendrik Jan Ankersmit; Bernhard Moser Journal: Br J Cancer Date: 2022-06-24 Impact factor: 9.075
Authors: Kathryn C Arbour; Jarushka Naidoo; Keith E Steele; Ai Ni; Andre L Moreira; Natasha Rekhtman; Paul B Robbins; Joyson Karakunnel; Andreas Rimner; James Huang; Gregory J Riely; Matthew D Hellmann Journal: PLoS One Date: 2017-08-03 Impact factor: 3.240
Authors: Joon Seon Song; Deokhoon Kim; Ji Hyun Kwon; Hyeong Ryul Kim; Chang-Min Choi; Se Jin Jang Journal: Front Oncol Date: 2019-10-15 Impact factor: 6.244
Authors: Valentina Tateo; Lisa Manuzzi; Andrea De Giglio; Claudia Parisi; Giuseppe Lamberti; Davide Campana; Maria Abbondanza Pantaleo Journal: Int J Mol Sci Date: 2020-11-28 Impact factor: 5.923